Fin

Beijing Yimiao Shenzhou Pharmaceutical Technology is a developer of CAR-T cell therapy and gene cell drugs for the treatment of cancer and malignant tumors. The company applies chimeric antigen receptor T-cell (CAR-T) technology to develop targeted immunotherapies for oncology applications. It also develops a gene engineering vector technology platform for the delivery of therapeutic genes, enabling the creation of advanced cell therapy products. The company focuses on leveraging genomics, immunotherapy, and cell therapy approaches to address unmet needs in cancer treatment. Founded in 2015 and headquartered in Haidian, Beijing, China, the company has raised $42.8 million in Series D funding from investors including China Life Insurance, GF Securities, SDIC Venture Capital Management, Shougang Fund, AAMA Chamber of Commerce, and Sherpa Ventures.